Skip to main content
. 2019 Nov 6;10(11):843. doi: 10.1038/s41419-019-2053-8

Fig. 8. miR-223 overexpression enhances the in vivo efficacy of doxorubicin for HCC.

Fig. 8

a After 2 weeks of treatment, mice of different groups were euthanized and tumors were dissected. b Volume of tumor xenografts in the control (red), AgomiR-223 (orange), doxorubicin (green), or doxorubicin plus AgomiR-223 (violet) groups. Relative tumor volume ratios (% of original volume when therapy initiated) are presented as the mean ± SD, n = 5 (***p < 0.001, control vs. doxorubicin alone; ###p < 0.001, doxorubicin plus AgomiR-223 vs. AgomiR-223 alone; &p < 0.05, doxorubicin plus AgomiR-223 vs. doxorubicin alone). c Body weight of mice in the control (red), AgomiR-223 (orange), doxorubicin (green), or doxorubicin plus AgomiR-223 (violet) groups (***p < 0.001, control vs. doxorubicin alone; ###p < 0.001, doxorubicin plus AgomiR-223 vs. AgomiR-223 alone)